{"id":"W4281263083","doi":"10.1016/j.jtct.2022.05.026","title":"Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States","year":2022,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":181,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Legend Biotech; Pharmacyclics; Kite Pharma; MorphoSys; Daiichi-Sankyo; Miltenyi Biotec; Omeros Corporation; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; TG Therapeutics; bluebird bio; Tessa Therapeutics; BeiGene; Atara Biotherapeutics; Kyowa Kirin Pharmaceutical Development; Janssen Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; National Cancer Institute; Servier; Gilead Sciences; Celgene; Novartis; AbbVie; Merck; Bristol-Myers Squibb; Cidara Therapeutics; AstraZeneca; Amgen; Seagen; Sierra Oncology; Astellas Pharma US","keywords":"Medicine; Internal medicine; Cohort; Odds ratio; Confidence interval; Oncology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006137591,0.0001058828,0.0001976301,0.0001630675,0.0001243922,0.000007386258,0.0001231793,0.00002067479,0.0003943386],"category_scores_gemma":[0.000001429399,0.00006169817,0.00009783136,0.0004278326,0.00006778174,0.00002214508,0.00000335201,0.00005628006,3.783971e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004799736,"about_ca_system_score_gemma":0.00006071987,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001047316,"about_ca_topic_score_gemma":0.0001379859,"domain_scores_codex":[0.9988875,0.0002291049,0.0002534147,0.0001462478,0.0003192033,0.0001645099],"domain_scores_gemma":[0.9989154,0.0006967001,0.00007646206,0.0002340835,0.00004838688,0.00002894529],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.01738753,0.003858186,0.006752062,0.0005309372,0.000233738,0.0000571446,0.06200947,0.0004012965,0.873351,0.000674514,0.00007704879,0.03466701],"study_design_scores_gemma":[0.02721222,0.006410724,0.01661479,0.00008607385,0.0002203134,0.00002085256,0.008475118,0.005289832,0.8844706,0.0001863294,0.05082924,0.0001839121],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.992597,0.004622106,0.0005104959,0.0007713343,0.0000294247,0.001190404,0.00009518535,0.000008150902,0.0001758538],"genre_scores_gemma":[0.9183747,0.07974514,0.00003841231,0.0002265677,0.00001897031,0.0002060954,0.0002244186,0.00001455786,0.001151092],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07512303,"threshold_uncertainty_score":0.4317731,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05882848758754067,"score_gpt":0.3396543056612309,"score_spread":0.2808258180736902,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}